Developer of a blood test system designed for the early detection of cancer.
Developer of a blood test system designed for the early detection of cancer.
Biotechnology📍 Palo Alto, CAFounded 2019
Current Valuation
$725M
as of 2024-Q2
PRIVATE
QL Price
$306.4M
-58% vs last round
QuantLogix's current estimate for Delfi Diagnostics, published 2026-09-27 — below the last disclosed round of $725M (2024-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$725M
2024-Q2
weight 0.21
Secondary market print
$152.97M
2026-06-27
weight 0.58
How this price has held up
No round has priced for Delfi Diagnostics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Delfi Diagnostics, 2026-09-27 (161c8feb63b8aa2e).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Delfi Diagnostics going public?
No. Delfi Diagnostics is private and has not filed to go public. There is no S-1 on file.
What is Delfi Diagnostics' valuation in 2026?
Delfi Diagnostics is valued at $725M as of 2024-Q2, set by its Series B ($100M, Jun 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Delfi Diagnostics filed an S-1?
No public S-1 is on file for Delfi Diagnostics.
How much has Delfi Diagnostics raised?
Delfi Diagnostics has raised $431.57M in total, most recently a Series B of $100M in Jun 2024.
Is Delfi Diagnostics publicly traded — can you buy Delfi Diagnostics stock?
No. Delfi Diagnostics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Delfi Diagnostics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2019
HQ
Palo Alto, CA
Employees
175
Total Raised
$431.57M
Last Round
Series B — $100M (Jun 2024)
IPO Status
private
Fundraising Status
Series B · $100M · 2y 3mo ago
privateTotal raised $431.57M
Secondary Market
Implied price / share
$1.02
Last round price / share
$4.84
vs last round
-78.9%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$100M
Jun 2024
—
$725M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
3
1 active · 0 recruiting
Focus areas
Lung Cancer
Head and Neck Cancer · Esophageal Cancer
Latest trial start
2023-10-31
Name-verified against lead sponsor "Delfi Diagnostics Inc." on ClinicalTrials.gov as of 2026-09-27. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▲ Hiring uptrend
+125% vs 2026-08
Open roles
9
via lever
Product-build share
78%
engineering, research, product, design
Trajectory
scaling
heavy product build — 78% of open roles are product-building functions (engineering/research/product) — 4 of 9 open roles are engineering.
Executive bench growing while hiring expands: 1 senior hire (CFO); open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Key Executive Moves
INCindy SorianoCFO · 2026-08-23
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Automation Engineer I/II (Contract)IVD Documentation Scientist, Manufacturing and Medical Device (Contract)Manager Equipment Service EngineeringSenior Clinical Laboratory Associate / Equipment Engineer (Contract)Senior Director, Clinical DevelopmentSenior Staff, Software Engineer
Counted from Delfi Diagnostics's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
MedicalHealth CareBiotechnologyHealth Diagnostics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q2. Refreshed quarterly.